SBShivang Bhakta

Shivang Bhakta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shivang Bhakta has a total of 96 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Recognizing the limitations of CLIF-C ACLF in predicting outcomes following liver transplantation in acute-on-chronic liver failure

    by Jorge Sinclair De Frias, Lorenzo Olivero, Trisha Singh, Ananya Vasudhar, Shivang Bhakta, Terri Menser, Philip Lowman, Devang Sanghavi, Juan Canabal, Kristopher P. Croome, et al.

  • Multidimensional Social Adversity and Mortality in People With HIV Infection and Heart Failure: Insights From NYC Health + Hospitals HIV–Heart Failure Cohort

    by Yi-Yun Chen, Pawel Borkowski, Luca Biavati, Natalia Nazarenko, Matthew Parker, Amrin Kharawala, Coral Vargas-Pena, Ishmum Chowdhury, Joshua Bock, Vibhor Garg, et al.

    BACKGROUND: Heart failure is an increasingly common comorbidity among people with HIV infection, complicating care and heightening the vulnerability of this population to social adversity (SA). However, the impact of different SA domains on outcomes in this population remains poorly understood. METHODS: We analyzed data on people with HIV infection and heart failure from the NYC 4H (NYC Health + Hospitals HIV–Heart Failure) cohort. Baseline multidimensional SA was assessed by licensed clinical social workers using standardized evaluations and grouped into 5 domains: economic hardship, health care access barriers, neighborhood or built environment instability, social support challenge, and psychobehavioral instability. We used multivariable adjusted Cox models to estimate hazard ratios (HRs) of all-cause, cardiovascular, and infection-related mortality and logistic regression to estimate odds ratios of 6-month rehospitalization risk. RESULTS: Among 1044 participants (62.9% male; mean age, 61.6 years), 601 (58%) reported at least 1 SA: economic hardship (n=130), limited health care access (n=155), unstable housing (n=129), social support challenge (n=179), or psychobehavioral instability (n=438). Over a mean follow-up of 3.8 years, exposure to any SA was associated with higher all-cause mortality (HR, 4.32 [95% CI, 3.03–6.14]), cardiovascular mortality (HR, 4.05 [95% CI, 2.17–6.83]), and infection-related mortality (HR, 2.37 [95% CI, 1.23–4.56]). Social support challenge (HR, 2.19 [95% CI, 1.35–3.55]) and psychobehavioral instability (HR, 1.96 [95% CI, 1.24–3.11]) were associated with higher cardiovascular mortality. Economic hardship (HR, 2.40 [95% CI, 1.22–4.70]) and social support challenge (HR, 3.09 [95% CI, 1.75–5.48]) were associated with higher infection-related mortality. Compared with patients without SA, those with environmental instability, psychobehavioral instability, or social support challenges had a 73% (adjusted odds ratio, 1.73 [95% CI, 1.15–2.06]), 75% (adjusted odds ratio, 1.75 [95% CI, 1.31–2.35]), and 44% (adjusted odds ratio, 1.44 [95% CI, 1.00-2.06]) higher risk of rehospitalization within 6 months, respectively. CONCLUSIONS: SA was significantly associated with mortality and rehospitalization among people with HIV infection and heart failure, with domain-specific pathways influencing specific outcomes. Multidimensional assessment of SA may offer a framework for domain-specific risk stratification in people with HIV infection and heart failure.


  • Open Access

    Multi-dimensional Social Adversity and Mortality Outcome in People Living With HIV and Heart Failure: Insights from NYC Health + Hospitals HIV-Heart Failure cohort

    by Yi-Yun Chen, Pawel Borkowski, Luca Biavati, Natalia Nazarenko, Matthew Parker, Amrin Kharawala, Coral Vargas-Pena, Ishmum Chowdhury, Joshua Bock, Vibhor Garg, et al.

    Background: Heart failure (HF) is an increasingly common comorbidity among people living with HIV (PLHIV), complicating care and heightening vulnerability of this population to social adversity (SA). However, the impact of different SA domains on outcomes in this population remains poorly understood. Methods: We analyzed data on PLHIV with HF from the NYC Health + Hospitals HIV-Heart Failure cohort. Baseline multidimensional SA was assessed by licensed clinical social workers using standardized evaluations and grouped into five domains: (1) economic hardship, (2) healthcare access barriers, (3) neighborhood/built environment instability, (4) social support challenge, and (5) Psycho-behavioral instability. We used multivariable adjusted Cox models to estimate hazard ratios (HRs) of all-cause, cardiovascular, and infection-related mortality; and logistic regression to estimate odds ratios (ORs) of 6-month rehospitalization risk. Results: Among participants 1044 (62.9% males, mean age: 61.6 years), 601 (58%) reported at least 1social adversities: economic hardship (n=130), limited healthcare access (n=155), unstable housing (n=129), social support challenge (n=179), or psycho-behavioral instability (n=438). Over a mean follow up of 3.8 years, exposure to any SA was associated with higher all-cause mortality (HR 4.32; 95% confidence interval [CI] 3.03–6.14), CV mortality (HR 4.05; 95% CI 2.17–6.83), and infection-related mortality (HR 2.37; 95% CI 1.23–4.56). Social support challenge (HR 2.19; 95% CI 1.35–3.55) and psycho-behavioral instability (HR 1.96; 95% CI 1.24–3.11) were associated with higher CV mortality; economic hardship (HR 2.40; 95% CI 1.22–4.70) and social support challenge (HR 3.09; 95% CI 1.75–5.48) were associated with higher infection-related mortality. Compared with patients without SA, those with an environment instability, psycho-behavioral instability, or social support challenges had a 73% (aOR 1.73; 95% CI, 1.15–2.06), 75% (aOR 1.75; 95% CI, 1.31–2.35), and 44% (aOR 1.44; 95% CI, 1.00-2.06) higher risk of rehospitalization within 6 months, respectively. Conclusion: SA was significantly associated with mortality and rehospitalization among PLHIV with HF, with domain-specific pathways influencing specific outcomes. A multidimensional assessment of social vulnerability may be useful to risk-stratify HF mortality risk in PLHIV.

  • Open Access

    Association of Neutralizing Antispike Monoclonal Antibody Treatment With Coronavirus Disease 2019 Hospitalization and Assessment of the Monoclonal Antibody Screening Score

    by Patrick W. Johnson, Katie L. Kunze, Jonathon W. Senefeld, Jorge E. Sinclair, Shahin Isha, Parthkumar H. Satashia, Shivang Bhakta, Jennifer B. Cowart, Wendelyn Bosch, Jack O’hOro, et al.


  • The association of acute COVID‐19 infection with Patient Safety Indicator‐12 events in a multisite healthcare system

    by Shivang Bhakta, Benjamin D. Pollock, Young M. Erben, Michael A. Edwards, Katherine H. Noe, Sean C. Dowdy, Pablo Moreno Franco, Jennifer B. Cowart

    Background: Patient Safety Indicator (PSI)‐12, a hospital quality measure designed by Agency for Healthcare Research and Quality (AHRQ) to capture potentially preventable adverse events, captures perioperative venous thromboembolism (VTE). It is unclear how COVID‐19 has affected PSI‐12 performance.Objective: We sought to compare the cumulative incidence of PSI‐12 in patients with and without acute COVID‐19 infection.Design, Setting, and Participants: This was a retrospective cohort study including PSI‐12‐eligible events at three Mayo Clinic medical centers (4/1/2020‐10/5/2021).Exposure, Main Outcomes, and Measures: We compared the unadjusted rate and adjusted risk ratio (aRR) for PSI‐12 events among patients with and without COVID‐19 infection using Fisher's exact χ2 test and the AHRQ risk‐adjustment software, respectively. We summarized the clinical outcomes of COVID‐19 patients with a PSI‐12 event.Results: Our cohort included 50,400 consecutive hospitalizations. Rates of PSI‐12 events were significantly higher among patients with acute COVID‐19 infection (8/257 [3.11%; 95% confidence interval {CI}, 1.35%–6.04%]) compared to patients without COVID‐19 (210/50,143 [0.42%; 95% CI, 0.36%–0.48%]) with a PSI‐12 event during the encounter (p < .001). The risk‐adjusted rate of PSI‐12 was significantly higher in patients with acute COVID‐19 infection (1.50% vs. 0.38%; aRR, 3.90; 95% CI, 2.12–7.17; p < .001). All COVID‐19 patients with PSI‐12 events had severe disease and 4 died. The most common procedure was tracheostomy (75%); the mean (SD) days from surgical procedure to VTE were 0.12 (7.32) days.Conclusion: Patients with acute COVID‐19 infection are at higher risk for PSI‐12. The present definition of PSI‐12 does not account for COVID‐19. This may impact hospitals' quality performance if COVID‐19 infection is not accounted for by exclusion or risk adjustment.


  • Open Access

    Clinical and laboratory profiles of the SARS-CoV-2 Delta variant compared with pre-Delta variants

    by Shivang Bhakta, Devang K. Sanghavi, Patrick W. Johnson, Katie L. Kunze, Matthew R. Neville, Hani M. Wadei, Wendelyn Bosch, Rickey E. Carter, Sadia Z. Shah, Benjamin D. Pollock, et al.


  • Open Access

    Low antispike antibody levels correlate with poor outcomes in COVID‐19 breakthrough hospitalizations

    by Devang K. Sanghavi, Shivang Bhakta, Hani M. Wadei, Wendelyn Bosch, Jennifer B. Cowart, Rickey E. Carter, Sadia Z. Shah, Benjamin D. Pollock, Matthew R. Neville, Sven P. Oman, et al.

    Background: While COVID‐19 immunization programs attempted to reach targeted rates, cases rose significantly since the emergence of the delta variant. This retrospective cohort study describes the correlation between antispike antibodies and outcomes of hospitalized, breakthrough cases during the delta variant surge.Methods: All patients with positive SARS‐CoV‐2 polymerase chain reaction hospitalized at Mayo Clinic Florida from 19 June 2021 to 11 November 2021 were considered for analysis. Cases were analyzed by vaccination status. Breakthrough cases were then analyzed by low and high antibody titers against SARS‐CoV‐2 spike protein, with a cut‐off value of ≥132 U/ml. Outcomes included hospital length of stay (LOS), need for intensive care unit (ICU), mechanical ventilation, and mortality. We used 1:1 nearest neighbor propensity score matching without replacement to assess for confounders.Results: Among 627 hospitalized patients with COVID‐19, vaccine breakthrough cases were older with more comorbidities compared to unvaccinated. After propensity score matching, the unvaccinated patients had higher mortality (27 [28.4%] vs. 12 [12.6%], p = 0.002) and LOS (7 [1.0–57.0] vs. 5 [1.0–31.0] days, p = 0.011). In breakthrough cases, low‐titer patients were more likely to be solid organ transplant recipients (16 [34.0%] vs. 9 [12.3%], p = 0.006), with higher need for ICU care (24 [51.1%] vs. 22 [11.0%], p = 0.034), longer hospital LOS (median 6 vs. 5 days, p = 0.013), and higher mortality (10 [21.3%] vs. 5 [6.8%], p = 0.025) than high‐titer patients.Conclusions: Hospitalized breakthrough cases were more likely to have underlying risk factors than unvaccinated patients. Low‐spike antibody titers may serve as an indicator for poor prognosis in breakthrough cases admitted to the hospital.


  • A systematic review and meta-analysis of racial disparities in deep vein thrombosis and pulmonary embolism events in patients hospitalized with coronavirus disease 2019

    by Shivang Bhakta, Young Erben, Devang Sanghavi, Susana Fortich, Yupeng Li, Mohammed M. Hasan, Yue Dong, Tara J. Brigham, Michael A. Edwards, James F. Meschia, et al.


  • Open Access

    Coronavirus Disease 2019 Vaccine-Breakthrough Infections Requiring Hospitalization in Mayo Clinic Florida Through August 2021

    by Wendelyn Bosch, Jennifer B Cowart, Shivang Bhakta, Rickey E Carter, Hani M Wadei, Sadia Z Shah, Devang K Sanghavi, Benjamin D Pollock, Matthew R Neville, Sven P Oman, et al.

    We characterized coronavirus disease 2019 (COVID-19) breakthrough cases admitted to a single center in Florida. With the emergence of delta variant, an increased number of hospitalizations was seen due to breakthrough infections. These patients were older and more likely to have comorbidities. Preventive measures should be maintained even after vaccination.